Skip to main content
Premium Trial:

Request an Annual Quote

Caliper to Consolidate West Coast R&D Operations in Alameda

NEW YORK (GenomeWeb News) – Caliper Life Sciences plans to consolidate its California operations in order to lower its facility costs and to increase the productivity of its research and development expenses, the company said today.
 
The move involves laying off around 13 employees and moving around 33 others who are principally engaged in R&D activities from its Mountain View facilities to those in Alameda.
 
The Hopkinton, Mass.-based company expects to incur around $3.7 million in costs associated with the move in 2008, but said it will save around $3.3 million annually once the changes have been fully implemented.
 
Caliper also said it has made several changes to lower general and administrative costs, and it now expects to report in its May 8 first-quarter earnings statement total revenue higher than the mid-point of its projected range of $26.5 million to $29.5 million.
 
The move also will result in roughly $400,000 in employee severance and retention costs in fiscal 2008 and around $2.7 million in facility abandonment charges that will take effect in the third quarter, it said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.